Most Indian pharma companies are now tweaking their business models, strategies, product portfolio, product mix and market presence to better face the industry headwinds and changing market dynamics. Among them, Cipla is the first to have taken this non-traditional and all-encompassing approach of investing in digital therapeutics.

To this end, the company acquired a 12% stake in Mumbai-based Wellthy Therapeutics in February this year. It is engaged in providing digital therapeutic services to simplify the disease management of patients of cardiovascular disorders. The partnership will enable Cipla to offer a combination of prescription drugs and artificial intelligence-powered digital therapies.

Later in April, it picked a 30% stake in South African firm Brandmed that has developed an integrated real-time monitoring model to address chronic diseases.Read More..